124 related articles for article (PubMed ID: 36253490)
1. Positive predictive value of LI-RADS US-3 observations: multivariable analysis of clinical and imaging features.
Tse JR; Shen L; Tiyarattanachai T; Bird KN; Liang T; Yoon L; Kamaya A
Abdom Radiol (NY); 2023 Jan; 48(1):271-281. PubMed ID: 36253490
[TBL] [Abstract][Full Text] [Related]
2. HCC screening with ultrasound: assessment of quality using ultrasound LI-RADS score.
King MJ; Lee KM; Rosberger S; Huang HH; Meza GH; Lewis S; Taouli B
Abdom Radiol (NY); 2023 Jan; 48(1):263-270. PubMed ID: 36243829
[TBL] [Abstract][Full Text] [Related]
3. Contrast-enhanced ultrasound Liver Imaging Reporting and Data System: Lights and shadows in hepatocellular carcinoma and cholangiocellular carcinoma diagnosis.
Vidili G; Arru M; Solinas G; Calvisi DF; Meloni P; Sauchella A; Turilli D; Fabio C; Cossu A; Madeddu G; Babudieri S; Zocco MA; Iannetti G; Di Lembo E; Delitala AP; Manetti R
World J Gastroenterol; 2022 Jul; 28(27):3488-3502. PubMed ID: 36158272
[TBL] [Abstract][Full Text] [Related]
4. LR-M Observations on Contrast-Enhanced Ultrasound: Detection of Hepatocellular Carcinoma Using Additional Features in Comparison With Current LI-RADS Criteria.
Xian MF; Huang Y; Xie WX; Pan KM; Zeng D; Huang H; Li MD; Xie XY; Kuang M; Lu MD; Chen LD; Wang W
AJR Am J Roentgenol; 2022 Jul; 219(1):76-85. PubMed ID: 34910538
[No Abstract] [Full Text] [Related]
5. Ultrasound (US) LI-RADS: Outcomes of Category US-3 Observations.
Sevco TJ; Masch WR; Maturen KE; Mendiratta-Lala M; Wasnik AP; Millet JD
AJR Am J Roentgenol; 2021 Sep; 217(3):644-650. PubMed ID: 34259543
[No Abstract] [Full Text] [Related]
6. Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1,006 nodules.
Terzi E; Iavarone M; Pompili M; Veronese L; Cabibbo G; Fraquelli M; Riccardi L; De Bonis L; Sangiovanni A; Leoni S; Zocco MA; Rossi S; Alessi N; Wilson SR; Piscaglia F;
J Hepatol; 2018 Mar; 68(3):485-492. PubMed ID: 29133247
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of LI-RADS US-2 Subthreshold Observations Detected on Surveillance Ultrasound.
Tse JR; Shen L; Bird KN; Yoon L; Kamaya A
AJR Am J Roentgenol; 2022 Nov; 219(5):774-783. PubMed ID: 35703411
[No Abstract] [Full Text] [Related]
8. Evaluation of LI-RADS 3 category by magnetic resonance in US-detected nodules ≤ 2 cm in cirrhotic patients.
Darnell A; Rimola J; Belmonte E; Ripoll E; Garcia-Criado Á; Caparroz C; Díaz-González Á; Vilana R; Reig M; Ayuso C; Bruix J; Forner A
Eur Radiol; 2021 Jul; 31(7):4794-4803. PubMed ID: 33409789
[TBL] [Abstract][Full Text] [Related]
9. Correlation of LI-RADS 3 or 4 Observations with Histopathologic Diagnosis in Patients with Cirrhosis.
Dunn C; Lin B; Rich NE; Patel MS; Gopal P; Singal AG
Clin Gastroenterol Hepatol; 2023 May; 21(5):1351-1353.e2. PubMed ID: 35307596
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic accuracy of contrast-enhanced ultrasound for the differential diagnosis of hepatocellular carcinoma: ESCULAP versus CEUS-LI-RADS.
Schellhaas B; Görtz RS; Pfeifer L; Kielisch C; Neurath MF; Strobel D
Eur J Gastroenterol Hepatol; 2017 Sep; 29(9):1036-1044. PubMed ID: 28562394
[TBL] [Abstract][Full Text] [Related]
11. The diagnostic value of contrast-enhanced ultrasound LI-RADS for hepatocellular carcinoma in patients with cirrhosis and chronic hepatitis B.
Yang D; Hu H; Li R; Tang CL; Ma KS; Guo DY
Abdom Radiol (NY); 2022 Feb; 47(2):630-639. PubMed ID: 34910237
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and clinical significance of discordant LI-RADS
Yokoo T; Singal AG; Diaz de Leon A; Ananthakrishnan L; Fetzer DT; Pedrosa I; Khatri G
Abdom Radiol (NY); 2020 Jan; 45(1):177-187. PubMed ID: 31342103
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic efficacy of contrast-enhanced ultrasound versus MRI Liver Imaging Reporting and Data System (LI-RADS) for categorising hepatic observations in patients at risk of hepatocellular carcinoma.
Li S; Zhou L; Chen R; Chen Y; Niu Z; Qian L; Fang Y; Xu L; Xu H; Zhang L
Clin Radiol; 2021 Feb; 76(2):161.e1-161.e10. PubMed ID: 33198943
[TBL] [Abstract][Full Text] [Related]
14. Clinical Outcomes of Patients With Suspicious (LI-RADS 4) Liver Observations.
Onyirioha K; Joshi S; Burkholder D; Yekkaluri S; Parikh ND; Singal AG;
Clin Gastroenterol Hepatol; 2023 Jun; 21(6):1649-1651.e2. PubMed ID: 35413448
[TBL] [Abstract][Full Text] [Related]
15. Hepatocellular carcinoma: Can LI-RADS v2017 with gadoxetic-acid enhancement magnetic resonance and diffusion-weighted imaging improve diagnostic accuracy?
Zhang T; Huang ZX; Wei Y; Jiang HY; Chen J; Liu XJ; Cao LK; Duan T; He XP; Xia CC; Song B
World J Gastroenterol; 2019 Feb; 25(5):622-631. PubMed ID: 30774276
[TBL] [Abstract][Full Text] [Related]
16. Analysis of Lipiodol uptake in angiography and computed tomography for the diagnosis of malignant versus benign hepatocellular nodules in cirrhotic liver.
Langenbach MC; Vogl TJ; von den Driesch I; Kaltenbach B; Scholtz JE; Hammerstingl RM; Gruber-Rouh T
Eur Radiol; 2019 Dec; 29(12):6539-6549. PubMed ID: 31236701
[TBL] [Abstract][Full Text] [Related]
17. Critical analysis of major and ancillary features of LI-RADS v2018 in the differentiation of small (≤ 2 cm) hepatocellular carcinoma from dysplastic nodules with gadobenate dimeglumine-enhanced magnetic resonance imaging.
De Gaetano AM; Catalano M; Pompili M; Marini MG; Rodríguez Carnero P; Gullì C; Infante A; Iezzi R; Ponziani FR; Cerrito L; Marrone G; Giuliante F; Ardito F; Rapaccini GL; Vecchio FM; Giraldi L; Manfredi R;
Eur Rev Med Pharmacol Sci; 2019 Sep; 23(18):7786-7801. PubMed ID: 31599447
[TBL] [Abstract][Full Text] [Related]
18. LI-RADS Version 2017 versus Version 2018: Diagnosis of Hepatocellular Carcinoma on Gadoxetate Disodium-enhanced MRI.
Lee SM; Lee JM; Ahn SJ; Kang HJ; Yang HK; Yoon JH
Radiology; 2019 Sep; 292(3):655-663. PubMed ID: 31310175
[TBL] [Abstract][Full Text] [Related]
19. Diffusion-weighted MRI as a screening tool for hepatocellular carcinoma in cirrhotic livers: correlation with explant data-a pilot study.
McNamara MM; Thomas JV; Alexander LF; Little MD; Bolus DN; Li YE; Morgan DE
Abdom Radiol (NY); 2018 Oct; 43(10):2686-2692. PubMed ID: 29500648
[TBL] [Abstract][Full Text] [Related]
20. Risk of Hepatocellular Carcinoma in Patients With Indeterminate (LI-RADS 3) Liver Observations.
Arvind A; Joshi S; Zaki T; Burkholder D; Parikh ND; Singal AG;
Clin Gastroenterol Hepatol; 2023 Apr; 21(4):1091-1093.e3. PubMed ID: 34902571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
